

# **CoCl(PPh<sub>3</sub>)<sub>3</sub> as Cyclotrimerization Catalyst for Functionalized Triynes under Mild Conditions**

Phillip Jungk, Fabian Fischer, Indre Thiel, Marko Hapke\*


Leibniz-Institut für Katalyse e.V. an der Universität Rostock  
Albert-Einstein-Str. 29a, D-18059 Rostock, Germany  
E-Mail: marko.hapke@catalysis.de


## **Supporting Information**


### Table of Contents


|                                                                           |     |
|---------------------------------------------------------------------------|-----|
| 1. Overview of compounds                                                  | S2  |
| 2. Literature synthesis procedures                                        | S7  |
| 3. Procedure and results for cyclizations with chiral anions as additives | S11 |
| 4. References                                                             | S13 |
| 5. NMR Spectra                                                            | S14 |


## 1. Overview of compounds














**52**




**53a**




**53b**




**53c**




**53d**




**53f**




**53g**




**53h**




**54**



**55**



**56**




**57**

## 2. Literature synthesis procedures

**1,4-Bis(prop-2-yn-1-yloxy)but-2-yne (2):**


Literature procedure:<sup>1</sup>



Spectral data are according to the literature.<sup>2</sup>

**1,4-Bis((3-phenylprop-2-yn-1-yl)oxy)but-2-yne (3):**


Literature procedure:<sup>1</sup>



Spectral data are according to the literature.<sup>2</sup>

**4-(Prop-2-yn-1-yloxy)but-2-yn-1-ol (12):**


Literature procedure:<sup>3</sup>



Spectral data are according to the literature.<sup>4</sup>


**1-(But-2-yn-1-yloxy)-4-(prop-2-yn-1-yloxy)but-2-yne (13):**

Literature procedure:<sup>2</sup>



**4-((Tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-ol (15):**


Literature procedure:<sup>5</sup>



Spectral data are according to the literature.<sup>6</sup>


**2-((4-(But-2-yn-1-yloxy)but-2-yn-1-yl)oxy)tetrahydro-2H-pyran (16):**

Literature procedure:<sup>7</sup>




**4-(But-2-yn-1-yloxy)but-2-yn-1-ol (17):**

Literature procedure:<sup>7</sup>




**1,4-Bis((3-(naphthalen-1-yl)prop-2-yn-1-yl)oxy)but-2-yne (19):**

Literature procedure:<sup>8</sup>



**4-Bromoquinoline (SI-I):**


Literature procedure:<sup>9</sup>



Spectral data are according to the literature.<sup>10</sup>

**1,4-Dibromobut-2-yne (SI-II):**


Literature procedure:<sup>3</sup>



Spectral data are according to the literature.<sup>11</sup>

**(3-Bromoprop-1-yn-1-yl)benzene (SI-III):**


Literature procedure:<sup>12</sup>



Spectral data are according to the literature.<sup>13</sup>

**3-(Naphthalen-1-yl)prop-2-yn-1-ol (SI-IV):**


Literature procedure:<sup>14</sup>



Spectral data are according to the literature.<sup>15</sup>


**3-(2-Methoxynaphthalen-1-yl)prop-2-yn-1-ol (7):**

Literature procedure:<sup>16</sup>




**1-(3-Bromoprop-1-yn-1-yl)naphthalene (SI-V):**

Literature procedure:<sup>17</sup>



**Diethyl-2-(prop-2-yn-1-yl)malonate (33a):**


Literature procedure:<sup>18</sup>



Spectral data are according to the literature.<sup>19</sup>

**Diethyl-2-(but-3-yn-1-yl)malonate (33b):**


Literature procedure:<sup>20</sup>



Spectral data are according to the literature.<sup>21</sup>

**Diethyl-2-(but-2-yn-1-yl)malonate (37):**

Literature procedure:<sup>22</sup>




### 3. Procedure and results for cyclizations with chiral anions as additives

Reaction procedure:


The respective triyne (**19**, 1 mmol),  $\text{CoCl}(\text{PPh}_3)_3$  (**1**, 5 mol% with regard to the triyne) and the respective chiral anion (5 mol% with regard to the triyne) were dissolved in THF (3 mL).  $\text{NEt}_3$  (3 drops) was added to the reaction mixture before the solution was stirred at 25 °C for 1 h. At the end of the reaction, the solvent was removed under reduced pressure and the residue purified by column chromatography using *n*-hex/EE (1:1) as the eluent to yield triaryl compound **39**. The ee values were determined by chiral HPLC-analysis (Cellulose 2, *n*-heptane/isopropanol 95:5, v/v, 1 mL/min or Cellulose 4, *n*-heptane/ethanol 98:2, v/v, 1 mL/min).

**Table S11: Screening of catalytic activity for 1 and *in situ* generated catalysts in combination with various chiral anion additives**




| # | Catalyst system                                                           | yield | d/l : meso |
|---|---------------------------------------------------------------------------|-------|------------|
| 1 | 1, no chiral anion                                                        | 59%   | 1.1 : 1    |
| 2 | 1 + L1                                                                    | 73%   | 1.3 : 1    |
| 3 | 1 + L1/AgOTf                                                              | 0%    | --         |
| 4 | 1 + L2/ $\text{NEt}_3$                                                    | 67%   | 1.1 : 1    |
| 5 | 1 + 58/ $\text{NEt}_3$                                                    | 94%   | 2.2 : 1    |
| 6 | 1 + 59/ $\text{NEt}_3$                                                    | 76%   | 1.2 : 1    |
| 7 | $\text{CoBr}_2/\text{dppe}/\text{Zn}/\text{ZnI}_2/\text{L2}/\text{NEt}_3$ | 41%   | 1: 2.2     |


Investigated chiral anions:



$\Delta$ -TRISPHAT tetrabutylammonium salt (**L1**)



(*R*)-(-)-VAPOL hydrogen phosphate (**L2**)



TRIP derivatives

**58:** R = *i*-Pr

**59:** R = CF<sub>3</sub>


#### **4. References**

1. Weding, N.; Jackstell, R.; Jiao, H.; Spannenberg, A.; Hapke, M., *Adv. Synth. Catal.* **2011**, 353, 3423.
2. Geny, A.; Agenet, N.; Iannazzo, L.; Malacria, M.; Aubert, C.; Gandon, V., *Angew. Chem. Int. Ed.* **2009**, 48, 1810.
3. Iafe, R. G.; Kuo, J. L.; Hochstatter, D. G.; Saga, T.; Turner, J. W.; Merlic, C. A., *Org. Lett.* **2013**, 15, 582.
4. Banti, D.; Groaz, E.; North, M., *Tetrahedron* **2004**, 60, 8043.
5. Tamura, S.; Doke, S.; Murakami, N., *Tetrahedron* **2010**, 66, 8476.
6. Huang, A.; Joseph-McCarthy, D.; Lovering, F.; Sun, L.; Wang, W.; Xu, W.; Zhu, Y.; Cui, J.; Zhang, Y.; Levin, J. I., *Bioorg. Med. Chem.* **2007**, 15, 6170.
7. Kaloko, J. J.; Teng, Y.-H. G.; Ojima, I., *Chem. Commun.* **2009**, 4569.
8. Shibata, T.; Tsuchikama, K.; Otsuka, M., *Tetrahedron: Asymmetry* **2006**, 17, 614.
9. Margolis, B. J.; Long, K. A.; Laird, D. L. T.; Ruble, J. C.; Pulley, S. R., *J. Org. Chem.* **2007**, 72, 2232.
10. Huiban, M.; Huet, A.; Barre, L.; Sobrio, F.; Fouquet, E.; Perrio, C., *Chem. Commun.* **2006**, 97.
11. Blond, G.; Bour, C.; Salem, B.; Suffert, J., *Org. Lett.* **2008**, 10, 1075.
12. McCarthy, T. D.; Naylor, A. WO 2013/102242 A1, **2013**.
13. Kwong, F. Y.; Li, Y. M.; Lam, W. H.; Qiu, L.; Lee, H. W.; Yeung, C. H.; Chan, K. S.; Chan, A. S. C., *Chem. Eur. J.* **2005**, 11, 3872.
14. Nanayakkara, P.; Alper, H., *Adv. Synth. Catal.* **2006**, 348, 545.
15. Feuerstein, M.; Berthiol, F.; Doucet, H.; Santelli, M., *Synthesis* **2004**, 1281.
16. Wessig, P.; Muller, G., *Chem. Commun.* **2006**, 4524.
17. Crich, D.; Wu, B., *Org. Lett.* **2006**, 8, 4879.
18. Mandal, J.; Krishna Prasad, S.; Rao, D. S. S.; Ramakrishnan, S., *J. Am. Chem. Soc.* **2014**, 136, 2538.
19. Wu, Z.; Minhas, G. S.; Wen, D.; Jiang, H.; Chen, K.; Zimniak, P.; Zheng, J., *J. Med. Chem.* **2004**, 47, 3282.
20. Sautier, B.; Lyons, S. E.; Webb, M. R.; Procter, D. J., *Org. Lett.* **2012**, 14, 146.
21. Day, J. E. H.; Sharp, S. Y.; Rowlands, M. G.; Aherne, W.; Workman, P.; Moody, C. J., *Chem. Eur. J.* **2010**, 16, 2758.
22. Shimamoto, T.; Chimori, M.; Sogawa, H.; Yamamoto, K., *J. Am. Chem. Soc.* **2005**, 127, 16410.

## 5. NMR Spectra


### Compound 2:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




### Compound 3:



$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)






**Compound 7:**



$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

**Compound 12:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)**Compound 13:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)


**Compound SI-I:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)




**Compound SI-II:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




**Compound SI-III:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




**Compound SI-IV:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




**Compound SI-V:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




# Compound SI-VI:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)





# Compound SI-VII: pathway A



$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)





$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)

**Compound 15:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)**Compound 16:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)


**Compound 17:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)**Compound 19:** $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)

**Compound 20:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 22:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 23:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 24:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)





**Compound 25:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)





$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)


26







<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)



27



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)


### Compound 33a:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




### Compound 33b:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




# Compound 34a:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 34b:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 34c:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 35a:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 35b:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 35c:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 36a:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)





# Compound 36b:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)


# Compound 36d:


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)






$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)


**Compound 37:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




# Compound SI-X:


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)



$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




$^{29}\text{Si}$  NMR ( $\text{CDCl}_3$ , 79 MHz)




# Compound 54:


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)



$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




$^{29}\text{Si}$  NMR ( $\text{CDCl}_3$ , 79 MHz)





# Compound SI-XI: pathway D

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

# Compound 42:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 43:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 44:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)





$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)





**Compound 45:**


d/l-form

 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)

**Compound 45:**

meso-form

 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)

The  $^{13}\text{C}$  NMR spectrum displays several peaks in the aromatic region (120–150 ppm) and a triplet for the solvent at 77 ppm. The peaks are labeled with their chemical shifts (ppm):

- 149.68
- 148.11
- 144.07
- 139.56
- 132.78
- 130.14
- 129.71
- 127.34
- 126.49
- 125.05
- 120.92
- 120.61
- 77.46 CDCl<sub>3</sub>
- 77.04 CDCl<sub>3</sub>
- 76.61 CDCl<sub>3</sub>
- 73.25
- 72.76



**Compound 46:**

meso-form

 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)



**Compound 47:**

d/l-form

 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)


**Compound 47:**

meso-form


 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)

**Compound 48:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 49:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 50:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




**Compound 51:**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)





$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)





**Compound 52:**

fraction 1:

 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)


**Compound 52:**

fraction 2:


 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz) $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)

# Compound 53a:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 53b:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz):




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz):




# Compound 53c:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz):




# Compound 53d:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)




# Compound 53f:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)





# Compound 53g:


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)

$^{29}\text{Si}$  NMR ( $\text{CDCl}_3$ , 79 MHz)



# Compound 57:

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)



$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)

